1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

<table>
<thead>
<tr>
<th>Pfizer Inc</th>
<th>Pfizer Ltd</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pfizer Pharmaceuticals Group</td>
<td>Ramsgate Road</td>
</tr>
<tr>
<td>235 East 42nd Street</td>
<td>Sandwich, Kent</td>
</tr>
<tr>
<td>New York, New York 10017</td>
<td>CT13 9NJ</td>
</tr>
<tr>
<td>1-212-573-2222</td>
<td>United Kingdom</td>
</tr>
<tr>
<td></td>
<td>+00 44 (0)1304 616161</td>
</tr>
</tbody>
</table>

Emergency telephone number: CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

| Material Name: Caduet (Amlodipine besylate/Atorvastatin calcium) tablets- 5 mg/10 mg and 10 mg/20 mg |
| Trade Name: CADUET | Chemical Family: Mixture |
| Intended Use: Pharmaceutical product for the treatment of high blood pressure (hypertension), high cholesterol (hyperlipidemia). |

2. HAZARDS IDENTIFICATION

| Appearance: 5 mg/10 mg: White film-coated tablets 10 mg/20 mg: Blue film-coated tablets |
| Additional Hazard Information: |
| Short Term: May cause eye irritation; May be harmful if swallowed. (based on components). |
| Antihypertensive drug: has blood pressure-lowering properties |
| Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver. |
| Known Clinical Effects: Adverse effects associated with therapeutic use of amlodipine include headache, swelling, dizziness, flushing, and palpitations. The most common adverse effects seen with the therapeutic use of atorvastatin include constipation, flatulence, upset stomach, and abdominal pain. Therapeutic use of atorvastatin has been associated with changes in liver function and muscle aches or weakness. |

| EU Indication of danger: Not classified |


Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.
3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS/ELINCS List</th>
<th>Classification</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine besylate</td>
<td>111470-99-6</td>
<td>Not listed</td>
<td>N;R51 Xn;R22  Xi;R41</td>
<td>6.94</td>
</tr>
<tr>
<td>Atorvastatin calcium</td>
<td>134523-03-8</td>
<td>Not listed</td>
<td>Not Listed</td>
<td>10.85</td>
</tr>
<tr>
<td>Starch, pregelatinized</td>
<td>9005-25-8</td>
<td>232-679-6</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Silicon dioxide, NF</td>
<td>7631-86-9</td>
<td>231-545-4</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>9004-34-6</td>
<td>232-674-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Calcium carbonate</td>
<td>471-34-1</td>
<td>207-439-9</td>
<td>Not Listed</td>
<td>*</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>209-150-3</td>
<td>Not Listed</td>
<td>*</td>
</tr>
</tbody>
</table>

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

Additional Information:
* Proprietary

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact:    Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:   Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:      Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:     Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, oxides of nitrogen, oxides of sulfur, hydrochloride, and other chlorine-containing compounds

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.
Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Minimize dust generation and accumulation. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Releases to the environment should be avoided.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Amlodipine besylate
Pfizer OEL TWA-8 Hr: 100µg/m³
Atorvastatin calcium
Pfizer OEL TWA-8 Hr: 50 µg/m³
Starch, pregelatinized
ACGIH Threshold Limit Value (TWA) 10 mg/m³ TWA
Australia TWA 10 mg/m³
Belgium OEL - TWA Listed
Bulgaria OEL - TWA Listed
Czech Republic OEL - TWA Listed
Greece OEL - TWA Listed
Ireland OEL - TWAs Listed
OSHA - Final PELS - TWAs: 15 mg/m³ total
5 mg/m³
Portugal OEL - TWA Listed
Spain OEL - TWA Listed
# 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Silicon dioxide, NF**

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia TWA</td>
<td>2 mg/m³</td>
<td>Listed</td>
</tr>
<tr>
<td>Austria OEL - MAKs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Germany - TRGS 900 - TWAs</td>
<td>4 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Germany (DFG) - MAK</td>
<td>4 mg/m³ MAK</td>
<td></td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>OSHA - Final PELs - Table Z-3 Mineral D:</td>
<td>- (80)/(% SiO2) mg/m³ TWA TWA-20 mppcf</td>
<td></td>
</tr>
<tr>
<td>Slovenia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>

**Microcrystalline cellulose**

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH Threshold Limit Value (TWA)</td>
<td>10 mg/m³ TWA</td>
<td></td>
</tr>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>OSHA - Final PELs - TWAs:</td>
<td>15 mg/m³ total</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Romania OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>

**Calcium carbonate**

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Bulgaria OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Czech Republic OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Estonia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>France OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Greece OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Hungary OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Latvia OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>OSHA - Final PELs - TWAs:</td>
<td>15 mg/m³ total</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>Poland OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Portugal OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Spain OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>

**Magnesium stearate**

<table>
<thead>
<tr>
<th>Country</th>
<th>Limit Value</th>
<th>Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACGIH Threshold Limit Value (TWA)</td>
<td>10 mg/m³ TWA</td>
<td></td>
</tr>
<tr>
<td>Australia TWA</td>
<td>10 mg/m³</td>
<td></td>
</tr>
<tr>
<td>Belgium OEL - TWA</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Ireland OEL - TWAs</td>
<td>Listed</td>
<td></td>
</tr>
</tbody>
</table>
8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Analytical Method:
Analytical method available for Amlodipine, Atorvastatin. Contact Pfizer Inc for further information.

Engineering Controls:
Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls:
Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment:
Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:
Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:
Wear safety glasses or goggles if eye contact is possible.

Skin:
Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:
If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Film-coated tablets
Molecular Formula: Mixture
Color: Blue White
Molecular Weight: Mixture

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.
Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.
Incompatible Materials: As a precautionary measure, keep away from strong oxidizers
Hazardous Decomposition Products: None known

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Calcium carbonate
Rat Oral LD50 6450 mg/kg
### 11. TOXICOLOGICAL INFORMATION

**Magnesium stearate**
- Rat  Oral  LD50  > 2000 mg/kg
- Rat  Inhalation  LC50  > 2000 mg/m³

**Microcrystalline cellulose**
- Rat  Oral  LD50  > 5000 mg/kg
- Rabbit  Dermal  LD50  > 2000 mg/kg

**Polysorbate 80**
- Rat  Oral  LD50  25 g/kg

**Silicon dioxide, NF**
- Rat  Oral  LD50  10 g/kg

**Amlodipine besylate**
- Rat (M)  Oral  LD50  393 mg/kg
- Rat (F)  Oral  LD50  686 mg/kg

**Atorvastatin calcium**
- Rat/Mouse  Oral  LD50  > 5000 mg/kg
- Rabbit  Dermal  LD50  > 2000 mg/kg

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

**Irritation / Sensitization: (Study Type, Species, Severity)**

**Microcrystalline cellulose**
- Skin Irritation  Rabbit  Non-irritating
- Eye Irritation  Rabbit  Non-irritating

**Amlodipine besylate**
- Eye Irritation  Rabbit  Severe
- Skin Irritation  Rabbit  Non-irritating
- Skin Sensitization - GPMT  Guinea Pig  Negative

**Atorvastatin calcium**
- Skin Sensitization - Beuhler  Guinea Pig  Negative
- Skin Irritation  Rabbit  Non-irritating
- Eye Irritation  Rabbit  Mild

**Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)**

**Amlodipine besylate**
- 3 Month(s)  Rat  Oral  3 mg/kg/day  NOAEL  Adrenal gland, Heart
- 1 Month(s)  Rat  Oral  3.5 mg/kg/day  LOEL  Heart
- 1 Year(s)  Rat  Oral  2 mg/kg/day  NOAEL  Adrenal gland Heart

**Atorvastatin calcium**
- 104 Week(s)  Dog  Oral  10 mg/kg/day  LOAEL  Liver
- 13 Week(s)  Mouse  Oral  100 mg/kg/day  LOAEL  Liver
11. TOXICOLOGICAL INFORMATION

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

**Amlodipine besylate**
- **Fertility and Embryonic Development**
  - Rat, Oral, 25 mg/kg/day, NOAEL, Not teratogenic, Maternal toxicity
- **Peri-/Postnatal Development**
  - Rat, Oral, 4 mg/kg/day, NOAEL, Fetotoxicity, Fetal mortality

**Atorvastatin calcium**
- **Reproductive & Fertility**
  - Rat, Oral, 20 mg/kg/day, NOAEL, Negative
- **Fertility and Embryonic Development**
  - Rat, Oral, 100 mg/kg/day, NOAEL, Not Teratogenic, Maternal Toxicity

**Embryo / Fetal Development**
- Rat, Oral, 10 mg/kg/day, NOAEL, Not Teratogenic, Maternal Toxicity, Fetotoxicity
- Rabbit, Oral, 20 mg/kg/day, NOAEL, Fetotoxicity

**Reproductive Effects**
No effects on fertility or reproductive performance were observed for amlodipine besylate or amlodipine maleate in the rat. Amlodipine besylate was reported to prolong gestation and duration of labor in rats. This effect has been similarly reported for other calcium channel blockers. No adverse effects on fertility or reproduction were observed in rats given atorvastatin calcium at doses up to 175 mg/kg/day in males or up to 225 mg/kg/day in females. Also, atorvastatin did not cause adverse effects on sperm or semen parameters, or on reproductive organ histology in dogs given doses of 10, 40, or 120 mg/kg/day for 2 years.

**Teratogenicity**
No evidence of embryotoxicity, fetotoxicity or teratogenicity was seen in rats or rabbits when amlodipine besylate was administered at dose levels up to 25 mg/kg. No birth defects were observed in rats or rabbits when atorvastatin calcium was given at maternally and fetally toxic doses. However, rare reports of birth defects have been linked to drugs of this class. Liver Adrenal glands Cardiovascular system

**Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

**Amlodipine besylate**
- **Bacterial Mutagenicity (Ames)**
  - Salmonella, E. coli, Negative

**Atorvastatin calcium**
- **In Vitro Bacterial Mutagenicity (Ames)**
  - Salmonella, E. coli, Negative

**Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

**Amlodipine besylate**
- 24 Month(s), Rat, Oral, in feed, 2.5 mg/kg/day, NOAEL, Not carcinogenic, No effects at maximum dose
- 24 Month(s), Mouse, Oral, in feed, 0.5 mg/kg/day, NOAEL, Not carcinogenic
11. TOXICOLOGICAL INFORMATION

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

Silicon dioxide, NF
IARC: Group 3

At increase risk from exposure: Individuals with a known history of hypersensitivity to this material or other materials in its chemical class and individuals with liver conditions and/or impaired liver function may be more susceptible to toxicity in cases of overexposure. Atorvastatin calcium as a HMG-CoA reductase inhibitor is contraindicated during pregnancy and in nursing mothers. Women of childbearing age or nursing mothers should exercise caution regarding exposure.

Additional Information: There have been rare reports of persistent elevations of liver function enzymes or myopathy resulting from therapeutic use of atorvastatin calcium.

12. ECOLOGICAL INFORMATION

Environmental Overview: This formulation has not been tested as a whole, the following apply to component substance(s): Harmful effects to aquatic organisms could occur.

Bioaccumulation and Toxicity: Moderate acute toxicity to aquatic organisms could occur. See aquatic toxicity data, below.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Amlodipine besylate
- *Daphnia Magna* OECD EC50 48 Hours 9.9 mg/L
- Rainbow Trout OECD LC50 96 Hours 14 mg/L
- Green algae OECD EbC50 72 Hours 0.28 mg/L
- Green Algae OECD ErC50 72 Hours > 0.91 mg/L

Atorvastatin calcium
- *Daphnia magna* (Water Flea) EC50 48 Hours 200 mg/L
- *Oncorhynchus mykiss* (Rainbow Trout) OECD LC50 96 Hours > 92 mg/L
- *Pseudokirchneriella subcapitata* (Green Alga) OECD EbC50 72 Hours 75 mg/L
- *Daphnia magna* (Water Flea) OECD LOEC 21 Days 0.27 mg/L
- *Pimephales promelas* (Fathead Minnow) OECD LOEC 32 Days 0.92 mg/L

Aquatic Toxicity Comments: A greater than (> ) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Bacterial Inhibition: (Species, Method, End Point, Duration, Result)

Amlodipine besylate
- *Nostoc sp.* (Freshwater Cyanobacteria) MIC 20 mg/L
- *Aspergillus Niger* MIC > 100 mg/L
- *Trichoderma viride* MIC > 100 mg/L
- *Clostridium perfringens* MIC > 100 mg/L
  - *Bacillus subtilis* MIC 80 mg/L

Atorvastatin calcium
- *Aspergillus niger* (Fungus) MIC > 1000 mg/L
- *Trichoderma viride* (Fungus) MIC > 1000 mg/L
12. ECOLOGICAL INFORMATION

Clostridium perfringens (Bacterium)  MIC  100  mg/L
Activated sludge  OECD  EC50  >1000  mg/L

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Canada - WHMIS: Classifications
WHMIS hazard class: Class D, Division 2, Subdivision B

Starch, pregelatinized
Inventory - United States TSCA - Sect. 8(b)  Listed
Australia (AICS): Listed
REACH - Annex IV - Exemptions from the obligations of Register: Present
EU EINECS/ELINCS List  232-679-6

Silicon dioxide, NF
15. REGULATORY INFORMATION

<table>
<thead>
<tr>
<th>Material Name</th>
<th>Inventory - United States TSCA - Sect. 8(b)</th>
<th>Australia (AICS):</th>
<th>EU EINECS/ELINCS List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium carbonate</td>
<td>Listed</td>
<td>Listed</td>
<td>231-545-4</td>
</tr>
<tr>
<td>Polysorbate 80</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td></td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>Listed</td>
<td>Listed</td>
<td>232-674-9</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose</td>
<td>Listed</td>
<td>Listed</td>
<td></td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>Listed</td>
<td>Listed</td>
<td>209-150-3</td>
</tr>
</tbody>
</table>

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R41 - Risk of serious damage to eyes.
R51 - Toxic to aquatic organisms.

Reasons for Revision:
Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 4 - First Aid Measures. Updated Section 5 - Fire Fighting Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 12 - Ecological Information. Updated Section 13 - Disposal Considerations. Updated Section 15 - Regulatory Information.

Prepared by:
Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.
End of Safety Data Sheet